Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 209522
Licensor grants an option to include under the License any or all of the peptides listed, together with all associated patents and patent applications listed, as applicable, and any corresponding foreign counterparts thereof, and all patents issuing thereon, including any division, continuation, continuation-in-part or substitution of any such patent application, and any reissue, extension, confirmation, registration, re-examination or inventors certificate of any such patent, together with any corresponding foreign counterparts of the foregoing.
Licensor grants an irrevocable option to include Japan in the Territory if Licensor regains rights to the Licensed Technology in the Field in Japan.
The licensed technology shall mean, collectively, the Licensed Patent Rights and Licensed Know-How.
The licensed know-how is
PADRE-specific HTL cell line and cell line for restimulation
Protocols for restimulation and testing of PADRE HTL line
Non-GMP peptides (PADRE, MAGE3.112I5, MAGE2.157)
Epitope-specific CTL cell lines (as available) and protocols for use Formulation development data for BCL-A2 peptides
IPSCIO Record ID: 237235
For the Peptide License Option, Licensor grants a non-exclusive option, the Peptide Option, to include under the License any or all of the peptides listed hereto, the Specified Peptides, together with all associated patents and patent applications for BCL-A1 Candidates, BCL-A3 Supertype Candidates, BCL-A24 Candidates, and, BCL-B7 Supertype Candidates, as applicable, and any corresponding foreign counterparts thereof, and all patents issuing thereon, including utility, model and design patents and certificates of invention, including any division, continuation, continuation-in-part or substitution of any such patent application, and any reissue, extension, confirmation, registration, re-examination or inventors certificate of any such patent, together with any corresponding foreign counterparts of the foregoing, collectively, the Additional Rights.
For the Japan Option, Licensor grants an irrevocable option, the Japan Option, to include Japan in the Territory. The Japan Option may be exercised at any time during the term of this Agreement.
For the New Peptide Sequences, Licensor may upon its sole discretion offer for license to Licensee any new peptide sequence together with all associated patents and patent applications owned or licensed by Licensor.
IPSCIO Record ID: 243435
IPSCIO Record ID: 237236
Licensee shall have the right to grant sublicenses.
PADREÂ® shall mean a peptide capable of binding antigen binding sites on major histocompatibility complex (MHC) molecules encoded by substantially all alleles of a DR locus, including, without limitation, a composition comprising a peptide recited in the claims of United States Patent Application Serial No. 08/121,101 and any patent applications, U.S., international and foreign, that derive priority from such patent application, such as continuing applications and any patents issuing therefrom. Such peptides are also referred to as pan DR binding peptides and include, without limitation, AKXV AA WTLKAAA,using the single letter designation for amino acids, wherein X is cyclohexylalanine or phenylalanine, and other peptides claimed and/or disclosed in the patent applications.
Product shall mean any product that contains, is comprised of or uses PADREÂ® in combination or association with any AutoVacâ„¢ Molecule.
The license is to use PADRE technology for use in connection with their AutoVacâ„¢ technology for controlling autoimmune diseases.
The PADRE technology consists of a family of small (13 amino acid), synthetic proprietary molecules that are potent immunostimulants, meaning that they stimulate the immune response.